Prothena Corporation PLC (PRTA) Actualités

Form 8-K - Current report

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Net cash provided by operating and investing activities was $15.8 million in the second quarter and net cash used by operating and investing...

Prothena to Report Second Quarter 2024 Financial Results on August 8

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash...

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities